These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8235433)

  • 1. Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m.
    Sciarretta G; Furno A; Mazzoni M; Ferrieri A; Malaguti P
    Scand J Gastroenterol; 1993 Sep; 28(9):783-5. PubMed ID: 8235433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
    Healey JN
    Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG; Healey JN; Reynolds JR
    Aliment Pharmacol Ther; 1987 Aug; 1(4):273-80. PubMed ID: 2979672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1990 Oct; 4(5):497-505. PubMed ID: 2129637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of mesalazine enemas in active and quiescent ulcerative colitis.
    van Bodegraven AA; Boer RO; Lourens J; Tuynman HA; Sindram JW
    Aliment Pharmacol Ther; 1996 Jun; 10(3):327-32. PubMed ID: 8791959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine.
    Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P
    Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrograde distribution of a new 5-aminosalicylic acid enema in patients with ulcerative colitis.
    Almer S; Ekberg S; Ström M
    Gastroenterol Clin Biol; 1992; 16(6-7):564-8. PubMed ID: 1526419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
    Gionchetti P; Campieri M; Belluzzi A; Boschi S; Brignola C; Miglioli M; Barbara L
    Aliment Pharmacol Ther; 1994 Oct; 8(5):535-40. PubMed ID: 7865646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis.
    Norlander B; Gotthard R; Ström M
    Aliment Pharmacol Ther; 1991 Jun; 5(3):291-300. PubMed ID: 1888828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of mesalamine enemas in patients with active distal ulcerative colitis.
    Chapman NJ; Brown ML; Phillips SF; Tremaine WJ; Schroeder KW; Dewanjee MK; Zinsmeister AR
    Mayo Clin Proc; 1992 Mar; 67(3):245-8. PubMed ID: 1545592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrograde spread of mesalazine (5-aminosalicylic acid)-containing enema in patients with ulcerative colitis.
    Tiel-van Buul MM; Mulder CJ; van Royen EA; Wiltink EH; Tytgat GN
    Clin Pharmacokinet; 1991 Mar; 20(3):247-51. PubMed ID: 2025983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.
    Varum F; Thorne H; Bravo R; Gilgen D; Hartig C; Nicolas GP; Wild D; Liakoni E; Haschke M
    Int J Pharm; 2022 Sep; 625():122055. PubMed ID: 35926752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of slow release mesalazine.
    De Vos M
    Clin Pharmacokinet; 2000 Aug; 39(2):85-97. PubMed ID: 10976656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis.
    Vitti RA; Meyers F; Knight LC; Siegel JA; Malmud LS; Fisher RS
    Dig Dis Sci; 1989 Nov; 34(11):1792-7. PubMed ID: 2582990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet.
    Hardy JG; Healey JN; Lee SW; Reynolds JR
    Aliment Pharmacol Ther; 1987 Jun; 1(3):209-16. PubMed ID: 2979223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastrointestinal pH profiles in patients with inflammatory bowel disease.
    Press AG; Hauptmann IA; Hauptmann L; Fuchs B; Fuchs M; Ewe K; Ramadori G
    Aliment Pharmacol Ther; 1998 Jul; 12(7):673-8. PubMed ID: 9701532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technetium-99 m labeling and evaluation of olsalazine: a novel agent for ulcerative colitis imaging.
    El-Kawy OA; Ibrahim IT; Farah K
    J Labelled Comp Radiopharm; 2015 Jun; 58(8):336-41. PubMed ID: 26031480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis.
    Campieri M; Lanfranchi GA; Brignola C; Bazzocchi G; Gionchetti P; Minguzzi MR; Cappello IP; Corbelli C; Boschi S
    Dis Colon Rectum; 1986 Feb; 29(2):108-10. PubMed ID: 3943419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalazine release from coated tablets: effect of dietary fibre.
    Riley SA; Tavares IA; Bishai PM; Bennett A; Mani V
    Br J Clin Pharmacol; 1991 Aug; 32(2):248-50. PubMed ID: 1657094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oroileal transit of slow release 5-aminosalicylic acid.
    Goebell H; Klotz U; Nehlsen B; Layer P
    Gut; 1993 May; 34(5):669-75. PubMed ID: 8504969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.